To overcome various challenges connected to using patient-derived organoids (PDOs) during large-scale screens, including assay reproducibility and scalability, a semi-automated bioprocess was developed to control the production of standardized PDOs at scale.
Image Credit: Molecular Devices
Molecular Devices built an end-to-end, automated workflow that starts with assay-ready colorectal cancer organoids, including establishment in screening, culture, and maintenance. Automation protocols were implemented for routine monitoring in culture, pre- and post-treatment, and compound effects were tracked over time.
Organoid growth and development were examined utilizing a deep learning-based image segmentation model that automated organoid segmentation. The organoids used had been extended before using Molecular Devices’* bioprocess and subsequently frozen, providing access to a high quantity of standardized, assay-ready organoids, which enabled a more statistically dynamic screen.
Molecular Devices tracked the effects of diverse compounds on colorectal organoid size, texture, morphology, and other phenotypic and morphological parameters via this method.
Molecular Devices’ findings showcase the higher potential of PDOs compared to other tissues in precision medicine and high-throughput drug discovery applications when employing automation alongside high-content imaging.
*Molecular Devices acquired Cellesce in 2022.
Download Now
About Molecular Devices UK Ltd
Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications.
Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion.
To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.
Sponsored Content Policy: AZO Life Sciences publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.